비소세포폐암 환자에 있어서 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors의 약효 및 rash 발생과 관련한 인자에 대한 연구
Factors associated with effectiveness of and rash occurrence by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in patients with non-small cell lung cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Currently lung cancer ranks second in cancer for incidence rate and is a disease that ranks first for a death rate by cancerous growth because it is already advanced at the time of diagnosis. The purpose of this paper was to analyze the factors that affect the effectiveness of and rash occurrence by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) in patients with non-small cell lung cancer. Methods: A retrospective chart review of 100 patients, who took EGFR TKI (erlotinib, gefitinib) among patients who were diagnosed with non-small cell lung cancer in a Hospital in Korea between May 2005 and February 2008, was conducted. The drug effectiveness was evaluated by Response Evaluation Criteria In Solid Tumor. Results: EGFR mutation was the only factor associated with drug response (complete response and partial response). When stable disease was added to drug response as the evaluation parameter, ECOG and rash as well as EGFR mutation were found to be important factors. Survival, however, was not affected by EGFR mutation. The factors influenced on survival were older age (≥65), low ECOG (1~2), adenocarcinoma and rash. In the case of rash, group with EGFR mutation or low ECOG showed significantly higher chance of occurrence. There was no significant difference in rash occurrence between gefitinib and erlotinib groups. Conclusions: Based on the results, EGFR mutation positive and low ECOG (1~2) were significantly important factors for both effectiveness of EGFR TKI and rash occurrence. Also, rash itself was found to be an independently significant factor for the disease control and survival. Therefore, while administering EGFR TKI, patients who have the factors associated with rash occurrence should be closely monitored for effective and safe drug therapy.
Abstract
Purpose: Currently lung cancer ranks second in cancer for incidence rate and is a disease that ranks first for a death rate by cancerous growth because it is already advanced at the time of diagnosis. The purpose of this paper was to analyze the factors that affect the effectiveness of and rash occurrence by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) in patients with non-small cell lung cancer. Methods: A retrospective chart review of 100 patients, who took EGFR TKI (erlotinib, gefitinib) among patients who were diagnosed with non-small cell lung cancer in a Hospital in Korea between May 2005 and February 2008, was conducted. The drug effectiveness was evaluated by Response Evaluation Criteria In Solid Tumor. Results: EGFR mutation was the only factor associated with drug response (complete response and partial response). When stable disease was added to drug response as the evaluation parameter, ECOG and rash as well as EGFR mutation were found to be important factors. Survival, however, was not affected by EGFR mutation. The factors influenced on survival were older age (≥65), low ECOG (1~2), adenocarcinoma and rash. In the case of rash, group with EGFR mutation or low ECOG showed significantly higher chance of occurrence. There was no significant difference in rash occurrence between gefitinib and erlotinib groups. Conclusions: Based on the results, EGFR mutation positive and low ECOG (1~2) were significantly important factors for both effectiveness of EGFR TKI and rash occurrence. Also, rash itself was found to be an independently significant factor for the disease control and survival. Therefore, while administering EGFR TKI, patients who have the factors associated with rash occurrence should be closely monitored for effective and safe drug therapy.
참고문헌 (32)
- 국가 암등록 사업 연례 보 고서 (2002 암 발생 현황), "보건 복지부 중앙 암 등록 본부", 보건 복지부 중앙 암 등록 본부, ~ (2002)
- Finkelstein DM, "Long-term survivors in metastatic non-small-cell lung cancer", J Clin Oncol, 4, pp.702~709 (1986)
- Bryant AS, "Differences in outcomes between younger and older patients with non-small cell lung cancer", Ann Thorac Surg, 85, pp.1735~1739 (2008)
- Belani CP, "Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer", J Clin Oncol, 23, pp.5883~5891 (2005)
- Ohe Y, "Randomized phase III study of cisplatin plus irinotecan verse carboplatin plus paclitaxel, cisplatin plus gemcitabine and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan", Ann Oncol, 18, pp.317~323 (2007)
- Fossella F, "Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group", J Clin Oncol, 21, pp.3016~3024 (2003)
- Smit EF, "European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975", J Clin Oncol, 21, pp.3909~3917 (2003)
- Zatloukal P, "Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer", Lung Cancer, 46, pp.87~98 (2004)
- Baselga J, "Why the epidermal growth factor receptor? The rationale for cancer therapy", Oncologist, 7, pp.2~8 (2002)
- Arteaga C, "Targeting HER1", EGFR: a molecular approach to cancer therapy, 2003, pp.30, 3~14
- Arteaga CL, "Epidermal growth factor receptor dependence in human tumors: more than just expression?", Oncologist, 7, pp.31~39 (2007)
- Arteaga CL, "Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site", J Biol Chem, 272, pp.23247~23354 (1997)
- Akita RW, "Preclinical studies with erlotinib (Tarceva)", Semin Oncol, 30, pp.15~24 (2003)
- Ohe H, "Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma", Cancer Sci, 99, pp.303~308 (2008)
- Jost M, "The EGF receptor-an essential regulator of multiple epidermal functions", Eur J Dermatol, 10, pp.505~510 (2000)
- Yano S, "Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition", Anticancer Res, 23, pp.3639~3650 (2003)
- Kimyai-Asadi A, "Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors", Arch Dermatol, 138, pp.129~131 (2002)
- Agero AL, "Dermatologic side effects associated with the epidermal growth factor receptor inhibitors", J Am Acad Dermatol, 55, pp.657~670 (2006)
- Pérez-Soler R, "Determinants of tumor response and survival with erlotinib in patients with nonesmall-cell lung cancer", J Clin Oncol, 22, pp.3238~3247 (2004)
- Soulieres D, "Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck", J Clin Oncol, 22, pp.77~85 (2004)
- Pérez-Soler R, "Can rash associated with HER1", EGFR inhibition be used as a marker of treatment outcome?, 2003, pp.17, 23~28
- Mohamed MK, "Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer", Ann Oncol, 16, pp.780~785 (2005)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Therasse P, "European Organisation for Research and Treatment of Cancer Data Center. Evaluation of response: new and standard criteria", Ann Oncol, 13, pp.127~129 (2002)
- Sequist LV, "Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutatioin testing", Oncologist, 12, pp.90~98 (2007)
- Ji H, "The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies", Cancer Cell, 9, pp.485~495 (2006)
- Lynch TJ Jr, "Epidermal Growth Factor Receptor Inhibitor Associated Cutaneous Toxicities", An Evolving Paradigm in Clinical Management Oncologist, 12, pp.610~621 (2007)
- Pérez-Soler R, "HER1", EGFR Inhititor-Associated Rash:Future Directions for Management and Investigation Outcomes from the HER1, Oncologist, pp.2007, 12[DOI]
- Kris MG, "Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial", JAMA, 290, pp.2149~2158 (2003)
- Herbst RS, "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial", J Clin Oncol, 20, pp.3815~3825 (2002)
- Fracasso PM, "A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing", Clin Cancer Res, 13, pp.986~993 (2007)